BackGraphite Bio Overview

Graphite Bio Net Tangible Assets

Track Graphite Bio's net tangible assets ($250M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$246.49M

Peer average

Loading

Graphite Bio Net Tangible Assets History

Loading

Graphite Bio vs. peers: Net Tangible Assets Comparison

Loading

Graphite Bio Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Graphite Bio (GRPH) FAQ

As of the most recent data (March 2026), GRPH shows a net tangible assets of $250M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GRPH's net tangible assets is now $250M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Graphite Bio is outperforming or lagging.

Tracking GRPH's net tangible assets over time shows whether Graphite Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $250M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Graphite Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $250M) with ownership activity and broader fundamentals.

Graphite Bio's net tangible assets is $250M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.